ライフサイエンスコーパス: memantine

1 43 [59%] who continued donepezil and started memantine).

2 which could be normalized by treatment with memantine.

3 rological function of mice than did ACS48 or memantine.

4 ical neurons more markedly than did ACS48 or memantine.

5 N-methyl-d-aspartic acid receptor antagonist memantine.

6 tective use-dependent NMDAR channel blocker, memantine.

7 benzoic acid (ACS48) with a NMDAR antagonist memantine.

8 t memantine, or continue donepezil and start memantine.

9 or ACS48, but suppressed by memantine and S-memantine.

10 obtained by linking together galantamine and memantine.

11 hose posthypoxic rats injected with 30 mg/kg memantine.

12 steadiness with gabapentin and lethargy with memantine.

13 ed the pro-aggressive effects of ketamine or memantine.

14 the NMDAR with the noncompetitive antagonist memantine.

15 s were prevented by the co-administration of memantine.

16 as the established NMDA receptor antagonist memantine.

17 , in contrast, was unchanged by both EPO and memantine.

18 s 10 mg of memantine or (2) placebo vs 20 mg memantine.

19 and 73 (25%) to continue donepezil and start memantine.

20 pants were analyzed (alpha tocopherol = 140, memantine = 142, combination = 139, placebo = 140), with

21 SZ patients (n=18) and HS (n=14) received memantine 20 mg (p.o.) and placebo over 2 test days in a

22 r continue donepezil 10 mg per day and start memantine 20 mg per day, for 52 weeks.

23 t memantine, discontinue donepezil and start memantine 20 mg per day, or continue donepezil 10 mg per

24 Memantine (20 mg) significantly enhanced PPI in CPD subj

25 pride (400 mg), the NMDA receptor antagonist memantine (20 mg), or placebo.

26 P1-01 (20 mg/kg per dose intraperitoneally), memantine (20 mg/kg per dose intraperitoneally), or vehi

27 Memantine (20 mg/kg, i.p.) reduced isoflurane-induced ca

28 Blocking NMDARs with memantine (30 mum) or GluN2B-containing receptors with i

29 festations," with greater frequencies in the memantine (31 events in 23 participants) and combination

30 reened, 81 were randomly assigned to receive memantine (39 patients) or placebo (42 patients).

31 Memantine (4 microM) inhibited isoflurane-induced elevat

32 tic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) for acquired nystagmus in 10 patie

33 42 [58%] who discontinued donepezil without memantine, 41 [54%] who discontinued donepezil and start

34 in patients who continued donepezil without memantine, 42 [58%] who discontinued donepezil without m

35 Patients were randomly assigned to a group: Memantine (5 mg/day) (n = 53) or Placebo (n = 75).

36 Preglaucomatous DBA/2J mice received memantine (5 mg/kg, intraperitoneal injection, twice dai

37 We randomly allocated 88 patients to receive memantine (72 [82%] had DAMES data and 75 [85%] had ABS

38 domly assigned to continue donepezil without memantine, 73 (25%) to discontinue donepezil without mem

39 e, 73 (25%) to discontinue donepezil without memantine, 76 (26%) to discontinue donepezil and start m

40 Memantine, a drug that blocks the ion channel formed by

41 Post-occlusion administration of memantine, a glutamate receptor antagonist that reduces

42 EPO effects were similar to those of memantine, a known neuroprotective agent.

43 Low doses of memantine, a low to moderate affinity open channel uncom

44 Memantine, a medication for Alzheimer's disease, increas

45 Memantine, a NMDA receptor antagonist approved for treat

46 Memantine acutely normalized cortical oscillatory dynami

47 In contrast, only memantine, administered systemically or intra-PLmPFC, in

48 l LTP, impairments that cannot be rescued by memantine administration.

49 ge depolarization nor maintained presence of memantine after agonist removal affected partial trappin

50 Administration of S-memantine after global cerebral ischemia and reperfusion

51 Incubation with S-memantine after reoxygenation following oxygen and gluco

52 cant reduction in only the 5.5 mm region and Memantine alone did not reach significance in either reg

53 nificant differences in the groups receiving memantine alone or memantine plus alpha tocopherol.

54 Memantine also holds promise to treat neuropsychiatric s

55 Memantine also inhibited Kir6.1 and Kir6.2 KATP channels

56 The structurally dissimilar NMDA antagonist memantine also reduced diabetic nephropathy, although it

57 Memantine, an adamantane derivative, has been used for t

58 We previously reported that memantine, an NMDA receptor antagonist, enhanced two bio

59 To test this hypothesis, the effect of memantine, an NMDA receptor antagonist, on the intensity

60 itory nerve compound action potential and/or Memantine, an NMDA receptor open channel blocker, would

61 totoxic insult and also to determine whether memantine, an NMDA-type glutamatergic channel blocker, i

62 Two key clinical trials of memantine and antioxidants for dementia in Down syndrome

63 Two such agents, memantine and dextromethorphan, are already in widesprea

64 st that currently hypothesized mechanisms of memantine and ketamine action should be reconsidered and

65 hibition of distinct NMDAR subpopulations by memantine and ketamine and help to explain their differe

66 Both memantine and ketamine antagonize N-methyl-D-aspartate r

67 basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on

68 Memantine and ketamine are clinically useful NMDA recept

69 ture drug development.SIGNIFICANCE STATEMENT Memantine and ketamine are NMDA receptor (NMDAR) channel

70 Therefore, differential inhibition by memantine and ketamine based on NMDAR location is likely

71 We found that memantine and ketamine differentially alter NMDAR desens

72 Equimolar memantine and ketamine had indistinguishable effects on

73 Here, we show that memantine and ketamine have contrasting effects on NMDAR

74 nefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that

75 N-methyl-D-aspartate (NMDA) antagonists like memantine and ketamine increase PPI, and under some cond

76 Memantine and ketamine inhibit NMDA receptors with simil

77 A prominent mechanistic difference between memantine and ketamine is the degree to which they are '

78 rch suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations

79 en hypothesized to result from inhibition by memantine and ketamine of overlapping but distinct NMDAR

80 Memantine and ketamine, voltage- and activation-dependen

81 tions for differences between the effects of memantine and ketamine.

82 n the primary outcome, 6 weeks CMAI, between memantine and placebo (memantine lower -3.0; -8.3 to 2.2

83 sulfide (Na(2)S) or ACS48, but suppressed by memantine and S-memantine.

84 s attenuated by the NMDA receptor antagonist memantine and the alpha 7 nicotinic acetylcholine recept

85 Memantine and the anti-NR1 antibody also attenuated a ra

86 Rats received systemic Memantine and/or Piribedil for 3 days before and 3 days

87 completed the 1-year memantine trial (21 on memantine) and also completed longitudinal ERP studies w

88 (3-thioxo-3H-1,2-dithiol-4-yl)-ben zamide (S-memantine) and examined its effects in vitro and in vivo

89 [54%] who discontinued donepezil and started memantine, and 43 [59%] who continued donepezil and star

90 76 (26%) to discontinue donepezil and start memantine, and 73 (25%) to continue donepezil and start

91 %, including the important drugs pregabalin, memantine, and the antimalarial artemisinin.

92 tagonist and antidepressant ketamine but not memantine, another NMDAR antagonist.

93 We confirmed that memantine antagonizes memory impairment in Alzheimer's m

94 the posthypoxic rats injected with 100mg/kg memantine are higher than those posthypoxic rats injecte

95 first report of the in vivo effectiveness of memantine as a neuroprotective agent against rotenone-in

96 ether, these findings substantiate a role of memantine as a potential pharmacological treatment for b

97 Using such low dose of memantine as adjuvant treatment for improving cognitive

98 Patients assigned to receive memantine, as compared with those assigned to receive me

99 lts provide evidence of target engagement of memantine, as well as therapeutically relevant informati

100 ly enhanced in the treated group, indicating memantine-associated improvement in attentional processe

101 ARs to investigate the actions of Mg(2+) and memantine at the two NMDARs displaying the largest diffe

102 ptic hippocampal microcultures, we show that memantine at therapeutic concentrations (1-10 microM) pr

103 NPI mean difference favoured memantine at weeks 6 (-6.9; -12.2 to -1.6; p = 0.012) an

104 Here, we report a novel target of the drug memantine, ATP-sensitive K(+) (KATP) channels, potential

105 we show in vivo that post-H/I treatment with memantine attenuates acute loss of the developing OL cel

106 thermore, the uncompetitive NMDAR antagonist memantine attenuates NMDA-evoked currents in developing

107 The NMDA receptor antagonist memantine attenuates these effects.

108 ocal evidence to explain the tolerability of memantine based on differential extrasynaptic/synaptic r

109 in, epicatechin, genistein, resveratrol, and memantine) before B(e)P exposure.

110 In contrast, memantine binding increases occupancy of GluN1/2A and na

111 Memantine block of glutamate-evoked currents is most pot

112 Memantine blocked apoptotic cell death in the GCL, incre

113 ining 128 CAG repeats (YAC128) with low-dose memantine blocks extrasynaptic (but not synaptic) NMDARs

114 We found that memantine blocks extrasynaptic NMDAR-mediated currents i

115 For example, memantine but not ketamine may inhibit extrasynaptic NMD

116 baseline condition, acute administration of memantine, but not CX516, reinstated experience-dependen

117 e speed (p < 0.001), gabapentin by 32.8% and memantine by 27.8%, and improved visual acuity (p < 0.05

118 the mechanism underlying partial trapping of memantine by recombinant NR1/2A NMDA receptors.

119 Genistein, resveratrol, and memantine can reverse the apoptosis and oxidant producti

120 e that the NMDA receptor partial antagonist, memantine, can prevent isoflurane-induced caspase-3 acti

121 ost encouraging preliminary evidence include memantine, carbamazepine and citalopram.

122 most promising preliminary evidence include memantine, carbamazepine, citalopram, and prazosin, but

123 this study, we recapitulate the ketamine and memantine clinical findings in mice, showing that ketami

124 We noted no effect of patients starting memantine compared with not starting memantine during th

125 As a result, therapeutic memantine concentrations should have negligible effects

126 arly during the development of the pathology memantine confers neuronal and cognitive protection whil

127 a-NAcc shell, but not core, microinfusion of memantine decreased binge-like eating.

128 The efficacy of donepezil and of memantine did not differ significantly in the presence o

129 Memantine did not improve significant agitation in peopl

130 uced both appetitive and aversive PEs, while memantine diminished appetitive, but not aversive PEs.

131 es of ketamine or memantine, or infusions of memantine directly into the prelimbic (PLmPFC) or infral

132 out memantine, discontinue donepezil without memantine, discontinue donepezil and start memantine 20

133 to continue donepezil 10 mg per day without memantine, discontinue donepezil without memantine, disc

134 We found that memantine dissociation from NR1/2A receptors after agoni

135 These protective doses of memantine do not affect normal myelination or cortical g

136 Cholinesterase inhibitors and memantine do not have regulatory approval in most of the

137 NMDAR antagonist, clinical data suggest that memantine does not exert rapid antidepressant actions fo

138 signaling coupled to NMDAR at rest, in that memantine does not inhibit the phosphorylation of eukary

139 Memantine dose-dependently decreased binge-like eating a

140 tarting memantine compared with not starting memantine during the first year (0.92 [0.58-1.45]) or th

141 ppocampal neurons, we show that ketamine and memantine effectively block NMDAR-mediated miniature exc

142 At therapeutic concentrations, memantine effectively blocks excessive extrasynaptic NMD

143 DAR antagonist or systemic administration of memantine effectively reversed nociceptive and mechanica

144 Here, we describe memantine effects on gammaEP and gammaPL in those subjec

145 ts, significant correlations between age and memantine effects were detected for gammaEP and gammaPL:

146 Memantine, EGTA, or autocamtide-2-related inhibitory pep

147 SZ patients had reduced gammaEP and gammaPL; memantine enhanced gammaEP and gammaPL (p<0.025 and 0.00

148 ine increase PPI, and under some conditions, memantine enhances MMN; these findings present a challen

149 age) were treated for 3 months with doses of memantine equivalent to those used in humans.

150 g that partial trapping does not result from memantine escape through open channels.

151 Animals not receiving memantine exhibited significantly lower mfVEP amplitudes

152 This differential effect of ketamine and memantine extends to intracellular signaling coupled to

153 pharmacological candidates in this group and memantine for neuropsychiatric symptoms.

154 Five participants in the memantine group and four controls died from serious adve

155 10 (11%) of 88 participants in the memantine group and six (7%) of 85 controls had serious

156 lly well tolerated; however, patients in the memantine group had more frequent cognitive adverse even

157 In the memantine group, these scores declined 1.98 units less (

158 mory performance after one year only for the memantine group.

159 After 12 weeks, Memantine-group required a somewhat lower methadone dose

160 Intra-ILmPFC memantine had no effect on aggression in either AHAs or

161 Memantine had no effect on these parameters in wild-type

162 at it still remains to be determined whether memantine has a role in milder agitation in AD.

163 Memantine has been used off-label to treat frontotempora

164 ings in mice, showing that ketamine, but not memantine, has antidepressant-like effects in behavioral

165 The NMDA antagonist, memantine, has dose-dependent effects on preconscious, a

166 herapeutic drug efficacy and tolerability of memantine have been attributed to fast kinetics and stro

167 Although vitamin E and memantine have been shown to have beneficial effects in

168 Memantine, however, induces far fewer behavioural side-e

169 rescription of a cholinesterase inhibitor or memantine hydrochloride from the Danish National Prescri

170 Acetylcholinesterase inhibitors and memantine hydrochloride were introduced in 61 (65.6%) pa

171 were also prevented by co-administration of memantine in a dose-dependent manner.

172 substudy of the randomized clinical trial of memantine in FXTAS sought to use the N400 repetition eff

173 Application of memantine in isolation was associated with a dose-depend

174 uble-blind, placebo-controlled Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOM

175 We provide evidence of the benefit of add-on memantine in opioid dependent patients undergoing MMT.

176 stic explanation for the limited efficacy of memantine in preventing memory loss in AD.

177 functional differences between ketamine and memantine in their ability to block NMDAR function at re

178 Some monkeys received memantine in their diet before and after ExpG induction

179 cts of the NMDA receptor partial antagonist, memantine, in H4-APP cells and brain tissue of naive mic

180 f IP ketamine, IP memantine, or intra-PLmPFC memantine increased aggression in AHAs, but only in the

181 Memantine increased CaMKII activity in the APP23 mouse h

182 S-memantine increased intracellular sulfide levels in huma

183 In addition, memantine induced an increase in long-term retinal energ

184 Ongoing studies will determine whether these memantine-induced changes predict acute pro-cognitive or

185 activity in the APP23 mouse hippocampus, and memantine-induced enhancement of hippocampal long-term p

186 deling showed that the voltage dependence of memantine inhibition also is altered by 1 mM Mg(2+)(o).

187 concentration (1 mM) of Mg(2+)(o) decreased memantine inhibition of NR1/2A and NR1/2B receptors near

188 In contrast, memantine inhibition of the other principal NMDAR subtyp

189 centrations, the genistein, resveratrol, and memantine inhibitors were able to reverse significantly

190 ffect after infusion of the NMDAR antagonist memantine into the nucleus accumbens and ventral tegment

191 We aimed to determine whether memantine is an effective treatment for FTD.

192 Memantine is an N-methyl-d-aspartate receptor antagonist

193 th Alzheimer's drugs is inadequate, although memantine is beneficial in transgenic mice.

194 Despite promising indications, memantine is not an effective treatment.

195 We tested the primary hypothesis, memantine is superior to placebo for clinically signific

196 6 weeks CMAI, between memantine and placebo (memantine lower -3.0; -8.3 to 2.2, p = 0.26); or 12 week

197 These findings indicate that memantine may benefit attentional processes that represe

198 these data suggest that NMDAR blockade with memantine may provide an effective pharmacological preve

199 The superficial binding site for memantine may, by causing partial trapping, contribute t

200 To test whether chronic memantine (MEM) treatment improves retinal function and

201 erformance in opioid dependents; the dose of memantine might be a worthy topic in future studies.

202 Low-dose memantine might have anti-inflammatory and neurotrophic

203 both approach and avoidance learning, while memantine mildly attenuated approach learning but had no

204 domly assigned to the experimental (5 mg/day memantine (MMT+M) or placebo (MMT+P) group: 57 in MMT+M,

205 Altogether, our studies show that memantine modulates Kir6.2 activity, and that the Kir6.2

206 d before agonist removal, whereas some bound memantine molecules dissociate after agonist removal, a

207 /d of alpha tocopherol (n = 152), 20 mg/d of memantine (n = 155), the combination (n = 154), or place

208 ety of other agents (eg, riluzole, ketamine, memantine, N-acetylcysteine, lamotrigine, celecoxib, ond

209 f tropisetron to the current AD therapeutics memantine (Namenda) and donepezil (Aricept), using simil

210 As a result, inhibition by memantine of GluN1/2A receptors in tsA201 cells and of n

211 , we examined the effects of NMDA antagonist memantine on attention and working memory.

212 We aimed to assess safety and efficacy of memantine on cognition and function in individuals with

213 Then, we tested the effects of memantine on food-seeking behavior, under a second-order

214 Finally, we evaluated the effects of memantine on FR1 responding for food, when microinfused

215 f therapy with a cholinesterase inhibitor or memantine on individualized assessment.

216 ences between the efficacies of ketamine and memantine on NMDAR-mediated neurotransmission that have

217 f the uncompetitive NMDA receptor antagonist memantine on palatable food-induced behavioral adaptatio

218 e assessed for the first time the effects of memantine on PPI and MMN in CPD subjects.

219 discontinuation of donepezil and starting of memantine on subsequent nursing home placement in patien

220 of food responding, we tested the effects of memantine on the Chow and Palatable food groups' intake.

221 Furthermore, we investigated the effects of memantine on the intake of food when it was offered in a

222 The effects of memantine on these parameters were investigated.

223 n, comparing either: (1) placebo vs 10 mg of memantine or (2) placebo vs 20 mg memantine.

224 because of many patients' preference to take memantine or cholinesterase inhibitors off-label rather

225 als were randomly assigned to receive either memantine or matched placebo tablets (1:1) in blocks of

226 omly allocated participants (1:1) to receive memantine or placebo for 52 weeks by use of a computer-g

227 e donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine.

228 intraperitoneal (i.p.) doses of ketamine or memantine, or infusions of memantine directly into the p

229 Moderate doses of IP ketamine, IP memantine, or intra-PLmPFC memantine increased aggressio

230 benefits of the combination of donepezil and memantine over donepezil alone.

231 Additional studies of memantine, perhaps in combination with other therapeutic

232 , as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an

233 s in the groups receiving memantine alone or memantine plus alpha tocopherol.

234 er the clinically tolerated NMDAR antagonist memantine possesses antidepressant properties.

235 Finally, memantine pre-incubation prevented Abeta-induced inhibit

236 We previously showed that memantine preferentially blocked neurotoxicity mediated

237 S-memantine prevented glutamate-induced glutathione deplet

238 (2)S-releasing NMDAR antagonist derivative S-memantine prevents ischemic neuronal death, providing a

239 hesis that uncompetitive NMDAR blockade with memantine prevents mitochondrial dysfunction-related neu

240 Memantine, previously reported as neuroprotective may at

241 quilibration for the two compounds, although memantine produced a more prominent fast component (62%

242 Combined treatment with Piribedil and Memantine produced a significant reduction in the noise-

243 We investigated whether add-on memantine reduced cytokine levels and benefitted patient

244 on compound related to the FDA-approved drug memantine, representing an uncompetitive/fast off-rate a

245 Memantine rescued both neuronal oxidative stress and the

246 atment for 2 weeks with an NMDAr antagonist (memantine) rescued cerebrovascular expression of claudin

247 genous NMDAR channel blocker that binds near memantine's binding site.

248 Research on memantine's mechanism of action has focused on the NMDAR

249 , by causing partial trapping, contribute to memantine's unique therapeutic utility.

250 re detected for gammaEP and gammaPL: greater memantine sensitivity on gammaEP and gammaPL were presen

251 ther NMDA open channel blockers ketamine and memantine showed a similar effect.

252 ound that a neuroprotective concentration of memantine shows little selectivity for extrasynaptic NMD

253 ntially alter NMDAR desensitization and that memantine stabilizes a Ca(2+)-dependent desensitized sta

254 Meta-analysis of memantine suggested that it is well tolerated but with f

255 ble-blind, placebo-controlled trial of 20 mg memantine taken orally daily for 26 weeks in patients wi

256 nsitivity to the channel blockers Mg(2+) and memantine that are dependent on the identity of the NR2

257 the presence of the NDMA receptor antagonist memantine, the calcium chelator EGTA, or a specific inhi

258 protection from Abeta-induced apoptosis than Memantine, the most recently FDA-approved drug for AD tr

259 hat partial trapping results from binding of memantine to two sites, a superficial 'non-trapping' sit

260 difference in IOP elevation exposure between memantine-treated and no-memantine-treated monkeys.

261 lum did not differ significantly between the memantine-treated and the saline-treated posthypoxic rat

262 ExpG eyes from memantine-treated animals had higher overall mean amplit

263 d in the photoreceptors of both vehicle- and memantine-treated glaucomatous retinas, but was increase

264 sed in the outer plexiform layer of only the memantine-treated glaucomatous retinas.

265 retinas but were significantly decreased in memantine-treated glaucomatous retinas.

266 After the treatment, memantine-treated mice had restored cognition and signif

267 on exposure between memantine-treated and no-memantine-treated monkeys.

268 Memantine treatment also was associated with a decline i

269 Memantine treatment had no effect on either the NPI (mea

270 Importantly, memantine treatment is able to partially normalize infor

271 These results suggest that memantine treatment may have beneficial effects on verba

272 Analysis also revealed that memantine treatment normalized the P2 habituation effect

273 These results suggest that the effects of memantine treatment on AD brain include disease modifica

274 tition effect to evaluate effects of chronic memantine treatment on verbal memory.

275 Memantine treatment showed no benefit in patients with F

276 Memantine treatment significantly increased RGC survival

277 ppocampal regions and if this is modified by memantine treatment.

278 ta from 41 patients who completed the 1-year memantine trial (21 on memantine) and also completed lon

279 in each arm) who completed both the primary memantine trial and two EEG recordings (at baseline and

280 There are no memantine trials in clinically significant agitation but

281 , two galantamine, one rivastigmine, and two memantine trials, comprising 3093 patients on the study

282 The combination of 5al, donepezil, and memantine (triple combination) produces synergistic effe

283 These data do not support memantine use in FTD.

284 ed trial and 149 people started the trial of memantine versus placebo.

285 Based on these results, oral memantine was administered to both children, with result

286 Memantine was also applied in isolation to characterize

287 n=17) and WT (n=17) oocytes, block by 10 muM memantine was also reduced (mean 26% [6] vs 75 [7], p<0.

288 Coapplication of memantine was associated with recovery of RGC tonic spik

289 For each condition, memantine was coapplied to determine its efficacy for re

290 Memantine was effective in reversing acute experimental

291 Memantine was generally well tolerated; however, patient

292 Although memantine was less effective than NGP1-01 (p<0.05), it s

293 treatment with cholinesterase inhibitors or memantine was permitted.

294 Finally, the NMDA-R antagonist memantine was protective against the manifestation of sy

295 Memantine was significantly better than placebo for cogn

296 S-memantine was synthesized by chemically combining a slow

297 Memantine was the most potent and genistein was the leas

298 harmacological approaches with Ro25-6981 and memantine, we provide evidence suggesting that chronic e

299 scores for the posthypoxic rats treated with memantine were significantly higher than those treated w

300 By contrast, high-dose memantine, which blocks both extrasynaptic and synaptic